ArticleMicrobiology spectrum2026
Implementation of multiplex PCR-based blood culture identification among hospitalized pediatric patients at a tertiary care center.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Conventional blood culture is the gold standard for pathogen identification for patients with sepsis, but its lengthy turnaround time-encompassing initial bottle incubation and subsequent phenotypic testing-may delay appropriate therapy. The multiplex PCR-based BIOFIRE Blood Culture Identification 2 (BCID2) panel enables earlier pathogen identification and improves patient outcomes. This study aimed to assess the impact of implementing the BCID2 panel versus conventional culture methods on clinical and microbiological outcomes in hospitalized pediatric patients. This case-control cohort study included 150 retrospective and 150 prospective hospitalized patients with positive blood cultures evaluated via parallel BCID2 and conventional culture. The antibiotic stewardship program (ASP) team provided antimicrobial recommendations based on BCID2 results, with final treatment decisions deferred to the attending physicians. Time to targeted therapy was calculated from the initial antibiotic dose-or blood culture collection if the patient was already on antibiotics-to the start of targeted antimicrobial therapy. The median age in the BCID2 group was significantly higher than the pre-BCID2 group, 2.8 vs 1.7 years, respectively ( IMPORTANCE: Bloodstream infection (BSI) remains a leading cause of pediatric morbidity and mortality worldwide. While conventional blood culture is the gold standard, its lengthy turnaround time often delays life-saving therapy. Rapid diagnostic testing (RDT), such as the BIOFIRE Blood Culture Identification 2 (BCID2) panel, is now recommended alongside antimicrobial stewardship programs (ASPs) to optimize clinical management. Our study demonstrates that implementing multiplex PCR-based RDT significantly improves patient outcomes by accelerating the time to targeted therapy. Furthermore, the integration of RDT into an ASP was associated with a significant reduction in both 30-day mortality and hospital length of stay. In conclusion, RDT-guided stewardship serves as both a vital diagnostic tool and a clinical engine that transforms the management of pediatric BSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.